Clinical Practice 2022 Taiwan lipid guidelines for primary prevention 03

Recommendation
臨床證據明顯的動脈粥狀硬化疾病, 需要立即降低 LDL-C. 
臨床證據不明顯, 單純是為了初級預防疾病, 建議依照危險等級分類. 來決定降血脂策略
Clinically significant ASCVD needs immediate and intensive reduction of LDL-C. (COR I, LOE A) For primary prevention in subjects without clinically significant ASCVD, risk stratification is necessary to determine the lipid lowering strategy. (COR I, LOE B)